The Firm is representing Blackstone in connection with its acquisition of Takeda Consumer Healthcare Company Limited (“TCHC”), a subsidiary of Takeda Pharmaceutical Company Limited and a leading provider of over-the-counter medicines in Japan, based on an enterprise valuation for TCHC of ¥242 billion (approximately US$ 2.3 billion). The acquisition marks Blackstone’s second private equity transaction in Japan’s healthcare sector following the acquisition of AYUMI Pharmaceutical in 2019. The transaction is expected to close by March 31, 2021 and is subject to regulatory approvals and customary closing conditions.
For more than 66 years, TCHC’s flagship vitamin drug Alinamin has been a staple product in Japanese households. In addition to Alinamin vitamin tablets and drinks, TCHC offers a platform of other over-the-counter products, including Benza Block, a leading symptom-based cold remedy.
The Simpson Thacher team for the transaction includes Tony King, Benjamin Moh and Sonya Ho (M&A); Shahpur Kabraji (Financing); Lori Lesser, Alysha Sekhon and Kate Mirino (IP); Jonathan Goldstein and Sarah Katz (Tax); and Etienne Renaudeau and Jessica Davies (Antitrust).